An interventional study of neuroendoscopic surgery and craniotomy in Intracerebral Haemorrhage, sponsored by Southwest Hospital, China. Recruiting at 5 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Southwest Hospital, China · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 123 studies in Cerebral Hemorrhage with a site in China — 59 open to participants now, 62 under way, 5 of them phase 3. Cerebral Hemorrhage · China.
Among the 123 studies in Cerebral Hemorrhage with a site in China, this one is the 26th largest by planned enrollment of the 77 interventional ones that give a count, is one of 20 that started in 2025, is one of 35 with no phase, reaches primary completion later than 43 of the 61 other live ones, and was the 94th registered.
458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.
Browse Cerebral Hemorrhage studies →59 of the 123 studies in Cerebral Hemorrhage with a site in China are open now. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 12–70
Jiangsu Province (Suqian) Hospital · Sites in China
Ages 65+
Beijing Tiantan Hospital · Sites in China
Ages 18–80
Yanyan Gong · Sites in China
Ages 18–85
Beijing Tiantan Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
123 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 20 · Phase 3 14 · Phase 4 4
First in 2005; this study’s year is marked. 20 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 384 is above the median of 100 across 269 interventional studies indexed under Cerebral Hemorrhage.
Median enrollment 180 across the 77 interventional studies, 664 across the 46 observational. Of the 31 that completed or were terminated, 4 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 123 have an industry lead sponsor. The 10 most frequent:
Southwest Hospital, China is the lead sponsor of 87 studies on the registry; 15 are open to participants now.
Southwest Hospital, China has 3 studies filed under Cerebral Hemorrhage — fewer than ten, so there is no comparison to draw.
14 of the studies in Cerebral Hemorrhage with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06868511Phase 3Beijing Tiantan HospitalNeuronavigation-assisted Stereotactic Puncture With Tenecteplase for Acute Intracerebral Hemorrhage | 2027-03-01 |
| NCT06688162Capital Medical UniversityMinimally Invasive Soft Channel Brain Haemorrhage Evacuation for Acute Basal Ganglia Haemorrhage--Small Hemorrhage Evacuation (MIRACLE-S) | 2026-11-30 |
| NCT06688201Capital Medical UniversityMinimally Invasive Soft Channel Brain Haemorrhage Evacuation for Acute Basal Ganglia Haemorrhage-- Large Hemorrhage Evacuation (MIRACLE-L) | 2026-11-30 |
| NCT03571763General Hospital of Shenyang Military RegionThe Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients | 2026-12-30 |
| NCT07311343Beijing Tiantan HospitalOral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 123 studies in Cerebral Hemorrhage with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, controlled clinical trial comparing neuroendoscopic hematoma removal to craniotomy in the treatment of large intracerebral hemorrhage.
Previous retrospective studies have demonstrated that neuroendoscopic surgery, compared to conventional craniotomy, significantly reduces operative duration and intraoperative blood loss, enhances hematoma evacuation rates, and improves postoperative outcomes, including neurological recovery, activities of daily living, and quality of life in patients with large cerebral hemorrhage. However, there is a paucity of prospective randomized controlled trials evaluating the efficacy of different surgical techniques for intracerebral hemorrhage. To address this gap, the investigators propose a multicenter, randomized, controlled clinical trial to compare the safety and efficacy of neuroendoscopic surgery versus craniotomy, aiming to provide evidence-based guidance for surgical decision-making in cerebral hemorrhage management.
The criteria were revised on the registry on Nov 17, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neuroendoscopic Surgery to remove intracranial hematoma
Procedure: neuroendoscopic surgery
Craniotomy to remove intracranial hematoma
Procedure: craniotomy
Subjects will receive Neuroendoscopic Surgery followed by standard medical management
Subjects will receive Craniotomy followed by standard medical management
The proportion of patients with Modified Rankin Scale (mRS) score 0-3
Functional outcome (comparing the intervention group to the control), assessed with the modified Rankin Scale (mRS) at 6 months.The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death.
Time frame: 180 days
mRS Shift Analysis of Neurological Improvement Between the Two Groups
The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death.
Time frame: 180 days
mortality
All cause mortality from onset to 180 days
Time frame: 30 days, 90 days and 180 days
Assessment of cognitive function with Mini-Mental State Examination (MMSE)
The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function.
Time frame: 90 days and 180 days
Length of ICU
Duration of stay in the ICU
Time frame: Number of days from admission, up to 180 days
Length of hospitalization
Duration of stay in the hospital
Time frame: Number of days from admission to discharge, up to 180 days
The proportion of patients with Modified Rankin Scale (mRS) score 0-3
Functional outcome (comparing the intervention group to the control), assessed with the modified Rankin Scale (mRS) at 6 months.The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death.
Time frame: 30 days and 90 days
Operation duration
The length of the operation
Time frame: From the beginning to the end of the surgery
Peroperative bleeding
The amount of blood lost during surgery
Time frame: During surgery
Intraoperative blood transfusion volume
Intraoperative blood transfusion volume
Time frame: During surgery
Incidence of rebleeding and infection
Incidence of rebleeding and infection in the two groups within 3 days, 7 days, and 30 days after randomization
Time frame: 3 days, 7 days, and 30 days after randomization
Incidence of complications
Incidence of other common complications within 180 days (epilepsy, hydrocephalus, pneumonia, gastrointestinal bleeding, deep vein thrombosis, cardiovascular and cerebrovascular events, etc.)
Time frame: 180 days
Incidence of adverse events and serious adverse events
Incidence of adverse events and serious adverse events in the two groups within 180 days
Time frame: 180 days
Plan to share: No
Started Jun 2025 (actual). Primary completion is estimated for Jun 2028, 36 months after the start.
Of 77 non-industry interventional studies with no phase under Cerebral Hemorrhage, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 75. This study's planned 36 months is close to that.
Counting every sponsor, half of 85 studies reached it within 38 months; a quarter within 19 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Southwest Hospital, China